74th Indian Pharmaceutical Congress 2025 Opens Registrations

74th Indian Pharmaceutical Congress 2025 Opens RegistrationsThe Indian Pharmaceutical Congress, 2025 (IPC), which is organized by the Association of Pharmaceutical Teachers of India (APTI), has opened its registration...

Stromal Changes May Signal Risk of Aggressive Breast Cancer

Scientists at the National Institutes of Health (NIH) have found that alterations in the structure and cell composition of breast connective tissue, or stroma, are associated with a heightened risk for aggressive breast cancer in women with benign...

Building a Successful Pharma Brand in India: The Role of Scientific Communication

In an interaction with India Pharma Outlook, C. Mukundan, Managing Director, Atozeta Health Solutions, shared his valuable inputs on how AI-driven personalization and omnichannel scientific engagement are redefining pharma brand-building...

GSK, iTeos Drop Lung Cancer Drug After Ineffective Trial Results

British pharmaceutical company GSK and iTeos Therapeutics announced on Tuesday that they had halted the development of belrestotug, an experimental treatment for lung cancer, after two tests showed that it was ineffective in halting the disease's pro

Johnson & Johnson Unveils Promising Tremfya Data for Ulcerative Colitis at DDW 2025

Johnson & Johnson announced compelling results from the phase 3 QUASAR long-term extension (LTE) study of Tremfya (guselkumab) in adults with moderately to severely active ulcerative colitis (UC). Presented at Digestive Disease Wee...

TPG to Acquire 35% Stake in SCHOTT Poonawalla from Serum Institute

SCHOTT Pharma, a global leader in drug containment and delivery solutions, has announced a binding agreement with TPG, a prominent alternative asset management firm, under which TPG will acquire a...

FDA Grants Fast Track Status to IGI's ISB 2001 for Difficult-to-Treat Multiple Myeloma

IGI, a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ISB 2001.

Biocon Biologics Expands U.S. Reach as Yesintek Wins Key Formulary Backing

Biocon Biologics has accomplished a major breakthrough in the U.S. with wide-ranging market access for Yesintek (ustekinumab-kfce), its biosimilar to Stelara, marking its first commercial launch in the country as a fully combined biosimilar company.

New Akums Patent Offers Safer Medication Delivery for Expectant Mothers

A leading contract research and manufacturing organization, Akums Drugs & Pharmaceuticals, has established a patent for its novel extended-release invention of doxylamine and pyridoxine.

ISRO & SCTIMST Partners to deliver Advanced Space Medicine in India

An innovation in Space Medicine has been made through the partnership of the Indian Space Research Organisation (ISRO), Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST),and the Department of S...